NALCN and cancer: To further validate Nalcn loss-of-function as a driver of cancer metastasis, we treated additional cohorts of V1KP;Nalcn+/+ (n = 37), V1KP;Nalcn+/Flx (n = 17) and V1KP;NalcnFlx/Flx (n = 8) mice with GdCl3 (2 μg per kg (body weight) per week).